Group 1 - The core focus of the company is on the research and development of oral insulin products, as well as the trade of beauty instruments and products [1] - The company aims to acquire commercially viable pharmaceutical products [1] - The company was formerly known as United Gene Technology Group and is now listed on the Hong Kong Stock Exchange under stock code 399 [1] Group 2 - As of the 2024 annual report, the company reported total revenue of 1.9296 million and a net loss of 319 million [2]